Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Fibrous Dysplasia/McCune-Albright Syndrome (DeFiD)
NCT05966064Phase 4Recruiting
- Start
- Jun 2023
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in fibrous dysplasia and McCune-Albright syndrome (MAS) comparing Denosumab Arm with Placebo Arm (2 arms). Primary endpoint: Maximal pain score on VAS at 12 months. Started Jun 2023; status: recruiting.
02
Drugs
denosumab
03
Conditions
fibrous dysplasiaMcCune-Albright syndrome (MAS)
Beyond the preview
Go deeper on NCT05966064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966064.